Class Considerations on Immunogenicity for AAV Gene Therapy Products: Assessing Current Practice and New Data

Watch Day 2 of this event!

Thursday January 23, 2025

Welcome

Antibody Testing and Companion Diagnostics: Avoiding Duplication of Efforts When Possible

• Panel Discussion

  • Moderator: Barry Byrne, MD, PhD, University of Florida

  • Additional Participants:

    • Joanne Lemmo, Sarepta Therapeutics, Inc.

    • Emily Coonrod, PhD, ARUP Laboratories, Inc. 

Break

Redosing Strategies in AAV Gene Therapies: Overcoming Neutralizing Antibodies

• Challenges and strategies for redosing, especially in seropositive patients. 

  • Speaker: Barry Byrne, MD, PhD, University of Florida 

• Discussion on the challenges and strategies for redosing, especially in seropositive patients. This session will highlight the use of Imlifidase as a potential approach to enable AAV redosing, with insights from Sarepta. 

  • Speaker: Louise Rodino-Klapac, PhD, Sarepta Therapeutics, Inc. 

• Panel Discussion 

  • Moderator: Aravind Asokan, PhD, Duke University School of Medicine 

  • Additional participants: Charles Askew, PhD, NabGen, Inc. 

Break

Immunosuppression in AAV Gene Therapies: What Does the Clinical Evidence Support?

• Variability of immunosuppression approaches, including the use of corticosteroids and phase-appropriate strategies. 

  • Speaker: Kevin Flanigan, MD, Nationwide Children’s Hospital 

• Panel Discussion 

  • Moderator: Barry Byrne, MD, PhD, University of Florida 

  • Additional participants: 

    • Jonathon Schwartz, MD, Rocket Pharmaceuticals, Inc.